This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Leukaemia
  • /
  • Management of patients with previously untreated c...
Journal

Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil

Read time: 1 mins
Published:1st Jul 2017
Author: Tam C, Kuss B, Opat S, Boulos J, Marlton P et al.
Availability: Free full text
Ref.:Intern Med J. 2017;47 Suppl 4:5-10.
DOI:10.1111/imj.13493
Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil


Patients with chronic lymphocytic leukaemia (CLL) are generally older, with many considered 'unfit' for fludarabine-cyclophosphamide-rituximab therapy. In these patients, the combination of obinutuzumab-chlorambucil may be an appropriate therapeutic choice. Obinutuzumab-chlorambucil has been demonstrated to improve overall survival rates compared to chlorambucil alone and to improve progression-free survival and overall response rates compared to rituximab-chlorambucil. This combination can lead to certain toxicities that need to be addressed through appropriate patient selection, pre-medication and management. In this paper, we discuss evidence-based and author-recommended practical management of first-line CLL patients receiving obinutuzumab-chlorambucil.

 

Read abstract on library site

Access full article